Evidence map›Paper›PMID 36641977›Full record

ArticlePhytomedicine : international journal of phytotherapy and phytopharmacology2023

Efficacy of Lianhua Qingwen for children with SARS-CoV-2 Omicron infection: A propensity score-matched retrospective cohort study.

Xiangru Xu, Hongze Wu, Guoqiang Jin, Jihan Huang, Jinhua Li, Jing Zhou, Min Cao, Ding Sun, Wen Zhang, Wei Peng and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Xiangru XuDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Hongze WuJiangxi Provincial Traditional Chinese Medicine Nephropathy Clinical Research Center, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang, Jiangxi, China.
Guoqiang JinDepartment of Health Management, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Jihan HuangCenter for Drug Clinical Research, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jinhua LiJiangxi Provincial Traditional Chinese Medicine Nephropathy Clinical Research Center, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang, Jiangxi, China.
Jing ZhouDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Min CaoDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ding SunDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Wen ZhangDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Wei PengDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yuting PuDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Caiyu ChenDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yuting SunDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Hongqiang YangDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Shuang ZhouAcupuncture and Massage College, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Electronic address: zhoushuang8008@163.com.
Bangjiang FangDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China; Institute of Critical Care, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Electronic address: fangbji@163.com.
Shanghai University of Traditional Chinese Medicine · CNJiujiang Maternal and Child Care Centres · CNNanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLianhua Qingwen Granules or Capsules (LHQW) has accumulated much research evidence in the fight against the coronavirus disease 2019 (COVID-19) epidemic. However, there are still few data on its efficacy and safety in children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. PURPOSE: To evaluate the efficacy and safety of LHQW in children with SARS-CoV-2 Omicron infection.

methodsWe conducted a single-center, propensity-score matched retrospective cohort study of children with SARS-CoV-2 Omicron infection in Shanghai New International Expo Center mobile cabin hospital between April 1st and June 1st, 2022. Eligible patients received either LHQW granules/capsules plus supportive care (LHQW group) or supportive care alone (control group). The primary outcome was the negative conversion time of nucleic acid. Secondary outcomes included the negative conversion rate of nucleic acid, the length of hospital stay, clinical disease progression, and cycle threshold [Ct] values for SARS-CoV-2 open reading frame [ORF1ab] or nucleocapsid [N] genes.

resultsOverall, 2808 patients were enrolled, and 346 patients in each group were included in the analysis. Among the propensity-score matched groups, LHQW treatment was associated with an accelerated negative conversion time of nucleic acid (median: 5 d vs. 6 d, Hazard ratio: 1.25, 95% CI: 1.08 - 1.46, Log-rank p < 0.001), a higher negative conversion rate of nucleic acid (Day 2 - 6: 2.9% vs. 0.6%, p = 0.036; 29.8% vs. 5.5%, p < 0.001; 42.5% vs. 24.3%, p < 0.001; 51.4% vs. 31.5%, p < 0.001; 63.3% vs. 55.2%, p = 0.030), shorter hospital stay (median: 10 d vs. 11 d, Hazard ratio: 1.50, 95% CI: 1.29 - 1.74, Log-rank p < 0.001), and lower rates of asymptomatic infection progressing to mild (37.9% vs. 46.5%, p = 0.021).

conclusionOur study suggested that LHQW treatment was associated with faster clinical recovery in children with SARS-CoV-2 Omicron infection.

Indexed as

COVID-19Nucleic AcidsCapsulesChildChinaHumansPropensity ScoreRetrospective StudiesSARS-CoV-2CapsulesNucleic AcidsCoronavirus disease 2019Lianhua QingwenOmicronPropensity score matchingRetrospective cohort study

Identifiers

PMID36641977
PMCPMC9831666
OpenAlexW4315434771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.